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8-Methoxypsoralen plus ultraviolet A light is suggested
to shift T lymphocytes from Th2 to Th1 cells. To
clarify this issue, we examined the effects of
8-methoxypsoralen/ultraviolet A on the expression/
production of cytokines in peripheral blood mono-
nuclear cells from normal subjects and a Se´zary
syndrome patient. 8-Methoxypsoralen/ultraviolet A
augmented the expression of mRNAs for interferon-g
and interleukin-2 and reduced those for interleukin-4
and interleukin-10. It seems that this enhancement of
Th1 cytokines is caused by increment of cytokine
production by Th1 cells but not by conversion of
Th2 cells to produce Th1 cytokines. The number
of interferon-g-secreting lymphocytes was markedly
increased in 8-methoxypsoralen/ultraviolet A-treated
peripheral blood mononuclear cells 20 h after
treatment, whereas that of Th2 cytokine-producing
Clinical efficacy of 8-methoxypsoralen (8-MOP) inconjunction with ultraviolet A light (UVA), referredto as PUVA, has been well documented in thetreatment of a number of skin disorders such aspsoriasis (Pathak and Fitzpatrick, 1992). In the more
recently developed method, the extracorporeal photochemotherapy
(ECP) or photopheresis, peripheral blood lymphocytes of the
8-MOP-administered patients are irradiated extracorporeally with
UVA and then returned to the patients (Edelson et al, 1987). ECP
was originally approved for the treatment of cutaneous T cell
lymphoma (CTCL), a malignancy derived from CD41 T helper
(Th) cells (Heald and Edelson, 1991). Various mechanisms have
been proposed to explain the mode of action by which PUVA and
ECP exert their biologic actions. As these psoralen photochemo-
therapies are used for immunologic disorders (Rook et al, 1990,
1992) or immunomodulatory purposes (Edelson et al, 1987; Besnier
et al, 1997), it is important to investigate functional changes in
immunocompetent cells phototreated with 8-MOP. Among the
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cells was decreased. Accordingly, the amount of
interferon-g was elevated in culture supernatants from
8-methoxypsoralen-phototreated peripheral blood
mononuclear cells, whereas interleukin-4 was signific-
antly reduced. This enhanced production of interferon-
g, however, was found only until 3 d after 8-methoxy-
psoralen phototreatment and was declined by 5 d after
treatment. Finally, 8-methoxypsoralen/ultraviolet A
treatment of T cells regulated their ability to induce
keratinocyte CD54 expression. Our results show that
8-methoxypsoralen/ultraviolet A has a transient but
biologically active Th1-skewing action in human T
cells, suggesting that 8-methoxypsoralen/ultraviolet A
exerts a beneficial therapeutic effect on Th2-mediated
or Th2-malignant diseases. Key words: interferon-g/
photochemotherapy/psoralen/T cells/ultraviolet light. J
Invest Dermatol 113:202–208, 1999
immunologic consequences, alterations in the cytokine production
(Tokura et al, 1991a; Tokura, 1999) as well as expression of surface
molecules (Kozenitzky et al, 1992; Urano et al, 1995; Cheng et al,
1996) are critical events in 8-MOP-phototreated cells. The vast
majority of studies have shown reduced production of cytokines
in 8-MOP/UVA-treated keratinocytes, lymphocytes, monocytes,
and endothelial cells (Tokura, 1999). For example, treatment of
peripheral blood mononuclear cells (PBMC) with 8-MOP/UVA
reduces the expression of interleukin (IL)-1β, IL-6, IL-8, and
tumor necrosis factor-α (Boehncke et al, 1994; Neuner et al, 1994).
This phototreatment at certain doses, however, can stimulate T
lymphocytes to produce certain cytokines (Saed and Fiverson,
1994), suggesting that some activational events may occur in
8-MOP-phototreated T cells.
CD41 Th cells can be divided into two distinct subsets with
mutually counteract properties: Th1 cells, producing interferon-γ
(IFN-γ) and IL-2, and Th2 cells, secreting IL-4, IL-5, and IL-10
(Mosmann and Coffman, 1989). Recently, 8-MOP/UVA has been
reported to skew T cell cytokine production from Th2 to Th1 type.
By competitive reverse transcription–polymerase chain reaction
(reverse transcription–PCR), Saed and Fiverson (1994) have shown
that 8-MOP/UVA augments IFN-γ mRNA expression in HUT-
78 cells, a malignant T cell line established from a patient with
Se´zary syndrome. A clinically oriented study by Di Renzo et al
(1997) demonstrated that PBMC of patients with the early stage
of CTCL produced higher levels of IL-4 and lower levels of IFN-γ
and IL-12. This showed that cytokine production was normalized
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after ECP treatment of 1 y. Considering that malignant T cells in
the majority of CTCL patients are of a Th2 type (Vowels et al,
1992; Saed et al, 1994; Rook et al, 1995; Yagi et al, 1996a), this
Th1 skewing effect of 8-MOP/UVA may at least partly be
responsible for the therapeutic effect of ECP.
This study was conducted to dissect whether the Th1-skewing
effect of 8-MOP/UVA effectively operates and is clinically relevant.
Our results show that the Th1-preponderance of 8-MOP-photo-
treated cells is seen in mRNA expression, the number of cytokine-
secreting cells, and the cytokines released into the supernatant.
Although the enhanced production of Th1 cytokines by the treated
T cells is transient, this change is biologically relevant when
examined by induction of CD54 expression in keratinocytes.
MATERIALS AND METHODS
Culture medium RPMI-1640 (Gibco BRL Life Technology, Grand
Island, NY) was supplemented with 10% heat-inactivated fetal calf serum,
2 mM L-glutamine, 5 3 10–5 M 2-mercaptoethanol, 10–5 M sodium
pyruvate, 25 mM HEPES, 1% nonessential amino acids, 100 units per ml
penicillin, and 100 µg per ml streptomycin (all from Gibco).
PBMC and T cell clones PBMC were isolated from normal subjects
and a 59 y old patient with Se´zary syndrome by the standard Ficoll-Paque
(Pharmacia, Uppsala, Sweden) method. The patient’s history and cytologic
features of his malignant T cells were described previously in detail (Seo
et al, 1998). Briefly, he had a marked peripheral blood lymphocytosis (300–
400 3 109 per liter) with a high CD4/CD8 ratio fluctuating from 9:1 to
370:1. Seventy to 90% of PBMC were CD31 CD41 CD7– CD45RO1
CD45RA– cells, typical of Se´zary cells (Wood et al, 1990). CD41CD7–
Se´zary cells exhibited a clonally rearranged band for a T cell receptor
β-chain (Cβ1) by Southern blot analysis and expressed mRNA for IL-4,
IL-5, and IL-10 but not for IL-2 or IFN-γ, indicating that the tumor cells
are of Th2 type (Seo et al, 1998). The patient had not received any
treatment except for topical application of corticosteroid ointments for at
least 2 wk before the study.
Keyhole limpet hemocyanin 1 I-Ak-specific murine T cell clones, 28-4
and 24-2 (Nakayama et al, 1988, 1989), were kindly provided by Dr.
Yoshihiro Asano, Department of Bacteriology, Ehime University; 28-4 and
24-2 cells belong to Th1 and Th2 cells, respectively, in their cytokine
profile (Nakayama et al, 1988, 1989). These cell clones were used 3 wk
after feeding with keyhole limpet hemocyanin (Sigma, St. Louis, MO;
final concentration, 10 µg per ml), feeder cells, and concanavalin A
(Con A)-stimulated rat spleen cell supernatants.
Human CD41 Th1 clones were generated from a normal subject by
culturing PBMC with mitomycin C-treated, autologous feeder cells and
recombinant IL-2 (5 units per ml; Genzyme, Boston, MA) after limiting
dilution (0.5 cells/well). Cells were restimulated with feeder cells and IL-2
and expressed CD3 and CD4 but not CD8 by flow cytometric analysis.
On reverse transcription–PCR analysis, the clones expressed mRNA for
IFN-γ and IL-2, but not IL-4 or IL-10.
Light source Black light (FL20SBLB) emitting UVA ranging from 320
to 400 nm with a peak emission at 365 nm were purchased from Toshiba
Electric (Tokyo, Japan). With a UV radiometer (Eisai, Tokyo, Japan), the
energy output of three 20 W tubes of black light at a distance of 20 cm
was 2.7 mW per cm2 at 365 nm and 0.17 mW per cm2 at 305 nm.
Treatment of cells with 8-MOP/UVA Stock solutions were prepared
by dissolving crystalline 8-MOP (Sigma) in absolute ethanol (100 µg per
ml) and diluted with phosphate-buffered saline (PBS; pH 7.4) just before
use. The procedure to treat cells with 8-MOP/UVA was described
previously (Tokura et al, 1991a, 1993). Briefly, PBMC and human CD41
T cell clones were incubated with 8-MOP for 30 min in the dark and
transferred to plastic dishes (Sumilon Dish, Sumitomo Bakelite, Tokyo,
Japan; 60 mm in diameter). The dishes were irradiated with UVA, whose
irradiance was measured through the plastic dishes. After irradiation,
cells were washed twice with PBS. The proportionate 8-MOP/DNA
photoadduct formation has been observed over an 8-MOP concentration
range of 1–200 ng per ml and a UVA dose range of 0.2–24 J per cm2 at
365 nm (Edelson et al, 1987; Tokura et al, 1991b). Furthermore, the plasma
concentration of 8-MOP in humans receiving oral PUVA therapy falls in
the range of 10–250 ng per ml (Gasparro et al, 1988). Thus, we chose
100 ng per ml of 8-MOP concentration plus 1 J per cm2 of UVA dose to
treat cells in this study unless otherwise mentioned. Treatment of keratino-
cytes with 8-MOP/UVA at these doses reduced their IL-1α production
by 55%–60% (Tokura et al, 1991a).
Reverse transcription–PCR for cytokines PBMC and 28-4 and 24-2
cells were untreated or treated with 8-MOP and/or UVA. PBMC were
cultured with 5 µg Con A (Sigma) per ml and 28-4 and 24-2 cells cultured
with Con-A-stimulated rat spleen cell supernatants for 2 h at 37°C in 5%
CO2 in air. A preliminary study showed that steady-state levels of cytokine
mRNA were too low to evaluate the modulatory effect of 8-MOP/UVA
and that incubation of PBMC with Con A augments mRNA expression
for all cytokines examined as compared with untreated cells. Therefore,
cells were exposed to Con A before extraction of RNA. In some
experiments, 8-MOP/UVA-treated PBMC were stimulated with solid-
phase anti-CD3 monoclonal antibody (MoAb) and soluble anti-CD28
MoAb (Thompson et al, 1989). Twenty-four well plates were precoated
with anti-mouse immunoglobulin G (1:500; goat affinity purified antibody;
Cappel, Aurora, OH) at 4°C overnight and coated with anti-human CD3
MoAb (2 µg per ml; OKT3; Ortho Diagnostic, Raritan, NJ). Cells were
cultured for 18 h in the plate in the presence of anti-CD28 MoAb (1 µg
per ml; PharMingen, San Diego, CA).
Total RNA was prepared from these cells, as reported previously
(Chomcznski and Sacchi, 1987). First-strand cDNA was reverse transcribed
using each RNA sample and was amplified by PCR with a RNA PCR
kit (GeneAmp RNA PCR Kit; Takara Biomedicals, Osaka, Japan) according
to the manufacturer’s directions. All pairs of primers for β-actin, IFN-γ,
IL-2, IL-4, and IL-10 in humans (Yagi et al, 1996a,b) and mice (Yagi et al,
1996c), and the procedure for PCR were described previously (Yagi et al,
1996a–c). The PCR products and DNA molecular weight marker VI
(Boehringer Mannheim GmbH, Mannheim, Germany) were separated by
electrophoresis in 2% agarose gels. The gel was stained with 1 µg per ml
ethidium bromide and amplified DNA bands were visualized with an UV
transilluminator. The density of the scanned band was quantitated by
image-analyzing software (NIH Image). The intensity of cytokine mRNA
expression was estimated by calculating the relative density of cytokine
PCR bands against β-actin in the same sample.
Reverse enzyme-linked immunospot (ELISPOT) assay The ELIS-
POT assay was performed as described (Czerkinsky et al, 1988; Kabilan
et al, 1990). Normal PBMC were untreated or treated with 8-MOP/UVA
and cultured for 20 h with or without Con A at 5 µg per ml. Nitrocellulose-
bottom MultiScreen-GV 96 well Filtration Plates (Millipore, Bedford,
MA) were coated with 100 µl of the first monoclonal antibody against
IFN-γ, IL-2, IL-4, IL-5, or IL-10 (PharMingen, San Diego, CA) in PBS
at a concentration of 10 µg per ml and incubated overnight at 4°C.
Unbound antibodies were removed by washing with sterile PBS and the
outer surface of the nitrocellulose membrane of the plate was treated with
PBS containing 5% fetal bovine serum to block nonspecific binding of
cytokines. The wells were filled in duplicate with 2 3 105 cultured PBMC
suspended in 100 µl of culture medium. After incubation for 20 h at 37°C
in 5% CO2 in air, the plates were rinsed four times with PBS by vigorous
shaking for 5 min. Then, 100 µl of PBS containing 5% fetal bovine serum
and the second anti-IFN-γ, anti-IL-2, anti-IL-4, anti-IL-5, or anti-IL-10
MoAb conjugated with biotin (PharMingen, 10 µg per ml) was added to
each well and incubated for 2 h at room temperature. After washing with
PBS, wells were exposed for 45 min to 100 µl of PBS containing avidin
conjugated with horseradish peroxidase (Gibco BRL Life Technology) at
a final concentration of 1 µg per ml. The enzyme substrate solution (3,39-
diaminobenzidine tetrahydrochloride-H2O2-chromagen substrate) was
added, and spots detectable as a brown precipitate were counted under
low magnification (340) with a stereomicroscope. The results were
expressed as the number of cytokine-forming spots per 106 cells.
Preparation of culture supernatants and assay for cytokines Normal
and Se´zary syndrome PBMC, and CD41 Th1 clones were treated with
8-MOP and/or UVA, and cultured in 24 well plates (Corning Glass Works,
Corning, NY; 3 3 106/1.5 ml of culture medium for PBMC and 3 3 105/
1.5 ml for T cell clones) in the presence of Con A (1 µg per ml unless
otherwise mentioned) at 37°C in 5% CO2 in air. The culture supernatants
were harvested after 3 d cultivation. In some experiments, supernatants
(95%) were harvested and replaced by fresh medium containing Con A
(1 µg per ml) on days 1, 3, and 5. As alternative stimulation, PBMC were
cultured in anti-CD3 MoAb-coated plates in the presence of anti-CD28
MoAb as described above. The amounts of IFN-γ and IL-4 present in
culture supernatants were measured by enzyme-linked immunosorbent
assay (ELISA) (Genzyme, or Special Reference Laboratories, Tokyo, Japan).
PBMC proliferation assay and enumeration of cultured PBMC
PBMC treated with 8-MOP and/or UVA (2 3 105 cells per well) were
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Figure 1. Elevated and depressed mRNA
expression for Th1 and Th2 cytokines,
respectively, in 8-MOP/UVA-treated PBMC
and murine Th1 and Th2 clones on reverse
transcription–PCR analysis. PBMC from the
Se´zary syndrome patient (A) and normal subjects
(B, C) and murine Th1 (28-4; D) and Th2 (24-2;
E) clones were treated with 8-MOP (100 ng per
ml) and/or UVA (1 J per cm2). They were
stimulated for 2 h with Con A (A, B) or Con-A-
stimulated rat spleen cell supernatants (D, E), or
with anti-CD3 and anti-CD28 MoAb for 18 h
(C), and subjected to reverse transcription–PCR.
Photographed DNA bands show PCR products,
whose size (base pairs, bp) was 661 bp for β-actin,
501 bp for IFN-γ, 458 bp for IL-2, 456 bp for
IL-4, and 352 bp for IL-10 in humans, and 762 bp
for β-actin, 307 bp for IFN-γ, 501 bp for IL-2,
401 bp for IL-4, and 210 bp for IL-10 in mice.
Graphed bars represent the relative density of
cytokine PCR bands against β-actin, analyzed
with NIH software. The data are a representative
of two series of independent experiments with
similar results.
cultured in triplicate in a final volume of 150 µl of culture medium in 96
well, flat-bottomed microtiter plates (Corning Glass Works) for 3 d and
pulsed with methyl 3H-thymidine (Amersham, Arlington, IL; 1 µCi per
well) 16 h before harvest. Con A (1 µg per ml) was added at the beginning
of the culture. The cells were collected on glass fiber filters using a cell
harvester (Cambridge Technologies, Watertown, MA) and their radio-
uptake was measured in a scintillation counter.
PBMC (2 3 106 per ml) untreated or treated with 100 ng 8-MOP per
ml and/or 1 J UVA per cm2 were cultured in the presence of Con A (1 µg
per ml) in duplicate in a final volume of 1 ml of culture medium in 24
well plates. On days 0–8, the number of viable cells, assessed by Trypan
Blue dye exclusion, was counted after pipetting the culture. As the cultured
cells were aggregated and made colonies, it was difficult to count the
absolute number of cells. Therefore, we used the relative number of cells
to untreated control, which represents (the number of PBMC treated with
8-MOP and/or UVA)/(the number of untreated PBMC) 3 100.
CD54 (intercellular adhesion molecule-1) expression on keratino-
cytes (Wakita et al, 1995) Normal human keratinocytes (Epipack,
Clonetics, CA) were grown in serum-free keratinocyte growth medium
(Gibco BRL, Gaithersburg, MD), supplemented with 10 ng per ml of
epidermal growth factor and 60 ng per ml of whole bovine pituitary
extract in 24-well plates. Keratinocytes at 90% confluency were used
for CD54 expression experiments by refeeding with 1 ml of medium
without epidermal growth factor or whole bovine pituitary extract.
Supernatants obtained from untreated or 8-MOP/UVA-treated PBMC
after 3 d-cultivation with or without Con A (1 µg per ml) were added to
keratinocyte cultures at a final dilution of 1/10. After 2 d cultivation,
single cell suspensions of keratinocytes prepared with trypsin/EDTA were
incubated with fluorescein isothiocyanate-conjugated anti-CD54 MoAb
(Immunotech, Marseilles, France) and analyzed in a FACScan (Becton
Dickinson, Mountain View, CA). Dead cells were identified by propidium
iodide uptake. Mean fluorescence intensity on the abscissa was expressed
as a logarithm.
Statistical analysis Student’s t test was used to determine statistical
differences between the means; p , 0.05 were considered significant.
RESULTS
Th1-preponderant augmentation of cytokine mRNA expres-
sion by 8-MOP/UVA The modulatory effect of 8-MOP/UVA
on mRNA expression for T cell cytokines was examined by reverse
transcription–PCR. PBMC from the Se´zary syndrome patient were
treated with 8-MOP and/or UVA and stimulated with Con A.
Treatment with 8-MOP or UVA alone reduced the expression of
all cytokines to various degrees (Fig 1A). The combination of
8-MOP and UVA, however, augmented the levels of mRNA for
IFN-γ and IL-2, whereas this treatment further reduced transcription
of IL-4 and IL-10. Similar results were obtained from experiments
in which normal subject’s PBMC were stimulated with Con A
(Fig 1B) or anti-CD3 plus anti-CD28 MoAb (Fig 1C). PBMC
from the Se´zary syndrome patient, however, exhibited more
pronounced changes in Th1 and Th2 cytokine production than
those of normal subjects, presumably because of the presence of a
high percentage (µ80%) of malignant Th2 cells. This notion was
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Figure 2. Increased Th1-producing and decreased Th2-producing
cell numbers in 8-MOP/UVA-treated PBMC in ELISPOT assay
analysis. Normal subject’s PBMC were treated with 8-MOP (100 ng per
ml) and/or UVA (1 J per cm2 at 365 nm), cultured with Con A (A) or
without Con A (B) for 20 h, and subjected to ELISPOT assay in triplicate.
The data are expressed as brown chromagen spot number per 106 cells.
The values of PBMC treated with 8-MOP or UVA alone were not
significantly changed compared with those of untreated PBMC. The data
are representative of three normal subjects with similar results. Vertical bars
represent SD. *p , 0.01, **p , 0.05, compared with the corresponding
no treatment group.
supported by the observation that PBMC from another patient
with Se´zary syndrome, which contained µ20% Th2 Se´zary cells,
showed a less marked increase in IFN-γ expression upon phototreat-
ment than those from the patient shown in Fig 1(A) (data
not shown).
When keyhole limpet hemocyanin-specific murine Th1 and
Th2 clones were tested, 8-MOP/UVA upmodulated the mRNA
expression of IFN-γ and IL-2 in Th1 cells (Fig 1D), but not IL-4
or IL-10 in Th2 cells (Fig 1E). Thus, Th1-skewing modulation
by 8-MOP/UVA was found at the mRNA level.
Increased numbers of Th1 cytokine-secreting cells in
8-MOP/UVA-treated PBMC The number of cytokine-secret-
ing T cells in normal PBMC untreated or treated with 8-MOP/
UVA was enumerated by ELISPOT assay after 20 h-cultivation
with Con A. As shown in Fig 2(A), lymphocytes secreting IFN-γ
were increased in number in 8-MOP/UVA-treated PBMC com-
pared with untreated cells. The number of IL-10-producing cells
was marginally decreased by this treatment, and IL-2-, IL-4-, or
IL-5-secreting cells were not significantly changed in number.
When examined in PBMC without Con A preincubation, the
absolute numbers of cytokine-producing cells were low, but
8-MOP/UVA augmentation of IFN-γ and inhibition of IL-10
were more clearly observed (Fig 2B). Furthermore, the number
of IL-2-secreting cells was remarkably increased with 8-MOP/
Figure 3. Increased IFN-g and decreased IL-4 amounts in the
culture supernatants from 8-MOP/UVA-treated PBMC. Normal
PBMC were treated with 8-MOP (100 ng per ml) and/or UVA (1 J per
cm2) and cultured for 3 d with Con A at 1 µg per ml (A) or with anti-
CD3 and anti-CD28 MoAb (B). The supernatants were assayed for IFN-γ
and IL-4 by ELISA. The relative value to untreated control represents
(concentration of experimental group)/(concentration of no treatment
group) 3 100, so that the values of no treatment groups are always 100.
Data are expressed as mean 6 SD of the relative values in two independent
experiments. The mean concentrations of no treatment groups in the two
experiments are as follows: IFN-γ of Con A-stimulated PBMC, 109 units
per ml; IL-4 of Con A-stimulated PBMC, 31 units per ml; IFN-γ of anti-
CD3/CD28-stimulated PBMC, 158 units per ml; and IL-4 of anti-CD3/
CD28-stimulated PBMC, 5.6 units per ml. *p , 0.01, compared with
corresponding 8-MOP or UVA alone group.
UVA. Thus, 8-MOP/UVA augmented the number of lymphocytes
producing Th1 cytokines.
Increased IFN-g and decreased IL-4 levels in culture super-
natants from 8-MOP/UVA-treated lymphocytes Normal
PBMC were treated with 8-MOP and/or UVA and cultured for
3 d in the presence of Con A at 1 µg per ml or in anti-CD3
MoAb-coated plates in the presence of anti-CD28 MoAb. IFN-γ
was augmented in supernatants by 8-MOP/UVA treatment, whereas
IL-4 was reduced in both Con A-stimulated (Fig 3A) and anti-
CD3 and anti-CD28 MoAb-stimulated PBMC (Fig 3B). In CD41
T cell clones from a normal subject and PBMC from a Se´zary
syndrome patient, that were stimulated with Con A, IFN-γ
production was marginally but significantly enhanced (38% and
25%, respectively) by 8-MOP/UVA. Thus, the Th1-skewing effect
of 8-MOP/UVA was also observed in the culture supernatants but
to a lesser degree than in the ELISPOT asssay.
8-MOP/UVA-treated PBMC rapidly lose the ability to pro-
duce increased IFN-g Treatment with 8-MOP/UVA leads to
inhibition of cell proliferation (Nielsen and Linnane, 1983; Kaidbey,
1985). When normal and Se´zary syndrome PBMC untreated or
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Figure 4. Decreased proliferative responses of 8-MOP/UVA-treated
PBMC to Con A and subsequent reduction in their number. (A, B)
Normal subject’s and Se´zary syndrome PBMC were treated with 8-MOP
(20, 50, or 100 ng per ml) and/or UVA (1 J per cm2) and cultured for 3 d
in the presence of Con A (1 µg per ml). DNA synthesis was measured by
the incorporation of methyl 3H-thymidine pulsed for the last 16 h. (C)
Normal PBMC were untreated or treated with 8-MOP (100 ng per ml)
and/or UVA (1 J per cm2) and cultured for 7 d in the presence of Con A
(1 µg per ml). On each day, the viable cells numbers were counted and
expressed as the relative number of cells to untreated control. *p , 0.001,
**p , 0.01, ***p , 0.05, compared with the corresponding no treatment
group. Vertical bars represent SD.
treated with 8-MOP and/or UVA were cultured with Con A for
3 d and DNA synthesis was measured, the proliferative responses
were inhibited by 8-MOP/UVA in an 8-MOP concentration-
dependent manner (Fig 4A, B). Following this inhibition of DNA
synthesis, 8-MOP/UVA-treated PBMC were decreased in number
compared with PBMC treated with 8-MOP or UVA alone
(Fig 4C). As the decrease in cell number began to be significant
on day 5, there was a time lag between the decline in DNA
synthesis and that in cell number.
We examined the time course of IFN-γ production by untreated
and treated PBMC. PBMC cultures were started on day 0 in the
presence of Con A at 1 µg per ml, and collection of supernatants
and replacement by the same volume of Con A (1 µg per ml)-
containing medium were performed on days 1, 3, and 5. As shown
in Fig 5, PBMC did not release substantial amounts of IFN-γ until
day 1. During days 1–3, the production of IFN-γ was higher in
8-MOP/UVA-treated cells than in untreated, 8-MOP-treated or
UVA-treated cells. On day 3, there was no difference in the number
of cells between the variously treated groups (see Fig 4C), suggesting
that IFN-γ production was also enhanced by 8-MOP/UVA treat-
ment when related to the number of viable cells. During days
3–5, IFN-γ release was reduced in 8-MOP/UVA-treated cells,
compared with the other groups. Thus, the enhanced ability of
8-MOP-phototreated PBMC to produce IFN-γ was transient and
declined rapidly in association with a decreased proliferative
response.
8-MOP/UVA treatment of T cells augments their capacity
to induce keratinocyte CD54 expression To evaluate the
Figure 5. Rapid decline in IFN-g production by 8-MOP/UVA-
treated PBMC. Normal subject’s PBMC were untreated or treated with
8-MOP (100 ng per ml) and/or UVA (1 J per cm2). Cultivation of these
cells was started on day 0 with Con A (1 µg per ml) in triplicate. Ninety-
five per cent of supernatants were harvested and replaced by the same
volume of Con A (1 µg per ml)-containing medium on days 1, 3, and 5.
The supernatants were assayed for IFN-γ. *p , 0.001, compared with the
other groups. Vertical bars represent SD.
Figure 6. Augmentative effect of 8-MOP/UVA on PBMC culture
supernatants to induce keratinocyte CD54 expression. Human
keratinocytes were incubated for 2 d with 3 d culture supernatants from
normal PBMC that were untreated or treated with 8-MOP (100 ng per
ml) and UVA (1 J per cm2) and incubated with or without Con A. The
levels of CD54 expression on keratinocytes were measured by flow
cytometry using anti-CD54 MoAb. Error bars represent SD.
Th1-enhancing and Th2-inhibitory effects of 8-MOP/UVA and
the overall biologic relevance, 3 d culture supernatants from
normal PBMC treated or not with 8-MOP/UVA were added to
semiconfluent cultures of normal human keratinocytes. After 2 d
cultivation with the supernatants, keratinocytes were tested for
their expression of CD54 by flow cytometry. IFN-γ is known to
enhance the expression of CD54 on keratinocytes (Griffiths et al,
1989), whereas IL-4 modestly reduces the IFN-γ-induced expres-
sion of CD54 when added simultaneously with IFN-γ and cultured
for 2 d (Viac et al, 1994). As shown in Fig 6, supernatants from
PBMC that were treated with 8-MOP/UVA and stimulated with
Con A promoted CD54 expression more markedly than those
from non-phototreated, Con-A-stimulated cells. No substantial
augmentation of CD54 expression was found with supernatants
from either PBMC nonstimulated with Con A. Thus, Th1-skewing
cytokine modulation by 8-MOP/UVA was also observed in this
assay system.
VOL. 113, NO. 2 AUGUST 1999 PSORALEN/UVA MODULATION OF T CELL CYTOKINE PRODUCTION 207
DISCUSSION
Our study provides a deeper insight into 8-MOP/UVA effects on
T cell cytokine production. In mRNA expression, a marked
enhancement of Th1 cytokines and a reduction in Th2 cytokines
were found in 8-MOP/UVA-treated PBMC. This was more
definitely observed in PBMC from a Se´zary syndrome patient than
those from normal subjects, presumably because Th2-type Se´zary
cells and Th1-type normal T cells clearly coexisted in the former
PBMC. Similarly, when murine Th1 and Th2 clones specific for
the same antigen were examined, the levels of mRNA for IFN-γ
and IL-2 were elevated in Th1 cells after 8-MOP/UVA, whereas
the treatment did not affect or it modestly decreased the expression
of IL-4 or IL-10 in Th2 cells. These results are in accordance with
the findings of Saed and Fiverson (1994), which show that treatment
of HUT-78 cells with 8-MOP/UVA increases IFN-γ mRNA levels.
HUT-78 cells have steady-state levels of mRNA for IFN-γ as
well as Th2 cytokines including IL-4, IL-5, and IL-10 (Saed and
Fiverson, 1994). Thus, 8-MOP/UVA is considered to enhance the
constitutional ability of HUT-78 cells to transcribe IFN-γ. On the
other hand, Se´zary Th2 cells used in this study expressed mRNA
for IL-4, IL-5, IL-10, but not IFN-γ or IL-2, when examined after
purification by CD4-positive and CD7-negative selections (Seo
et al, 1998). Furthermore, the expression of IFN-γ mRNA was
not detected by reverse transcription–PCR even after mitogenic
stimulation of these purified Se´zary cells. Therefore, it is most
likely that the 8-MOP/UVA-induced elevation of IFN–γ in Se´zary
syndrome PBMC is due to increased IFN-γ expression by normal
Th1 cells but not to conversion of malignant Th2 cells to produce
IFN-γ. In addition, 8-MOP/UVA is thought to downmodulate
mRNA expression for Th2 cytokines, IL-4 and IL-10, in Se´zary
cells. The reduced production of Th2 cytokines may contribute to
further augmentation of cytokine production by normal Th1 cells
as a result of abrogation of antagonistic effects of Th2 cytokines.
Such an antagonistic interaction between Th1 and Th2 cells may
exaggerate Th1-skewing cytokine production in Th1/Th2-mixed
populations.
Increased Th1 and decreased Th2 cytokine production was also
clearly observed at the protein level in 8-MOP/UVA-treated
PBMC by ELISPOT assay, which exhibited an increase in the
number of IFN-γ-secreting or IL-2-secreting lymphocytes at 20 h
after phototreatment. Accordingly, when IFN-γ was quantitated
in the culture supernatants, its level was elevated in 8-MOP-
phototreated cells, whereas IL-4 was significantly reduced. The
treated cells, however, rapidly lost the IFN-γ-producing ability
during 3–5 d after phototreatment. The proliferation of 8-MOP-
phototreated PBMC was dramatically decreased by day 3 after
treatment, and 8-MOP/UVA has been reported to retard cell cycle
progression, leading to cell cycle arrest and apoptotic cell death
(Johnson et al, 1996). In association with this inhibition of prolifera-
tion, the enhanced ability of phototreated T cells to synthesize Th1
cytokines may be lowered, accounting for the only transient
increase in released IFN-γ. Although transient, 8-MOP/UVA
exerted a substantial biologic effect on T cells when released
cytokines were bioassayed in keratinocyte CD54 expression, which
is promoted by IFN-γ (Griffiths et al, 1989) and reduced by IL-4
(Viac et al, 1994). Therefore, repeated infusions of 8-MOP/
UVA-treated lymphocytes in ECP potentially led to continuous
restoration of Th1/Th2 balance in Th2-dominant individuals. In
fact, the impaired ability of PBMC to produce Th1 cytokines was
normalized in CTCL patients after 1 y of ECP (Di Renzo et al,
1997). This notion may also be supported by an older observation
that IFN-like activity in sera of patients with psoriasis was increased
following PUVA treatment (Diezel et al, 1983).
The Th1-skewing action of 8-MOP/UVA is thought to particip-
ate in the therapeutic mechanisms of 8-MOP photochemotherapy.
Tumor-specific CD81 cytotoxic cells are proved to exist in PBMC
of Se´zary syndrome (Berger et al, 1996; Seo et al, 1998). On one
hand, 8-MOP/UVA promotes the expression of major histo-
compatibility complex class I molecules and cell-adhesion molecules
on the surface of tumor cells (Schmitt et al, 1995; Gasparro et al,
1997), which potentially enhances the action of cytotoxic T cells.
On the other hand, the tumoricidal function of CD81 cells is
profoundly activated by Th1 cytokines, IL-2 and IFN-γ (Seo et al,
1998) and inhibited by Th2 cytokines (Salvucci et al, 1996). Thus,
Th1-preponderant modulation by 8-MOP/UVA may lead to
activation of cytotoxic T cells. 8-MOP/UVA is considered to exert
beneficial effects on CTCL as a cytokine modifier, in addition to
an antigen enhancer. The relative Th2 cytokine-inhibitory action
also may be involved in the therapeutic mechanism of ECP for
atopic dermatitis (Richter et al, 1998). It is suggested that ECP at
least partly shares the therapeutic action with IFN-γ administration,
which is used in the treatment of Th2-type CTCL (Yagi et al,
1996a) and Th2-mediated cutaneous disorders (Fushimi et al, 1996;
Tokura et al, 1997; Stevens et al, 1998).
Our study indicates that this photoactivatable agent is not merely
cytotoxic but can induce some activational events. The molecular
mechanisms of this activation remain to be elucidated, but several
possibilities can be proposed. Like ionizing radiation (Valerie et al,
1995), transcription factors such as nuclear factor-κB might be
activated by psoralen photodamage, leading to an upregulation of
cytokine genes (Gasparro, 1996). Mitogen-activated protein kin-
ase(s) is involved in the signaling pathway for the production of
IFN-γ (Rincon et al, 1998). Prolonged activation of mitogen-
activated protein kinase by low doses of radiation (Carter et al,
1998) raises the possibility that 8-MOP/UVA promotes IFN-γ-
producing signaling pathway by activating mitogen-activated pro-
tein kinase(s). More specifically to 8-MOP phototreatment, in cells
transfected with chloramphenicol acetyltransferase gene under the
control of the human immunodeficiency virus-1 promoter,
8-MOP/UVA was proved to activate the promoter of this virus
(Zmudzka et al, 1993). Finally, p53 assists in the recognition of
DNA damage and causes cell cycle arrest at the G1 phase until the
damage has been repaired (Chen et al, 1998). There is a difference
in DNA content between cells treated with 8-MOP/UVA and
those with UVA alone (Hornicek et al, 1989). 8-MOP/UVA may
thus induce G1 arrest and apoptosis (Johnson et al, 1996). As the
late G1 phase is the most cytokine-productive period in Th1 cells
(Dro¨ge, 1986), cytokines may be produced at high levels when p53
is induced by 8-MOP/UVA (Gasparro, 1996). Signal transduction
pathways of Th1 and Th2 cells are different from each other in
terms of participation of protein tyrosine kinases (Tamura et al,
1995) and mitogen-activated protein kinases (Rincon et al, 1998).
Future studies are required for clarifying the mechanisms underlying
Th1-preponderant activational events induced by 8-MOP and
UVA.
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